Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
AADI Transcript
Aadi Bioscience, Inc. (AADI) Q2 2024 Earnings Call Transcript
Unknown8-10
The earnings call presents a mixed picture: stable financial performance with a decrease in net loss and increased FYARRO sales, but ongoing financial challenges and risks from clinical trials. The Q&A section highlights management's uncertainty in key areas, like TSC1 and 2 expectations, and vague responses on sales potential, which may concern investors. Despite positive cash flow and a promising market opportunity, uncertainties in trial outcomes and market adoption, along with lack of guidance, suggest a neutral short-term stock price movement.
Aadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call Transcript
Unknown3-13
The earnings call presents a mixed picture. Financial performance shows positive revenue growth and a strong cash position, but there are concerns about increased R&D expenses and net losses. The Q&A highlights ongoing trials with some promising interim results, but uncertainties remain about future trial outcomes and competitive pressures. Management's reluctance to provide specific guidance on FYARRO sales adds to the uncertainty. Overall, these factors suggest a neutral stock price movement in the short term.
Aadi Bioscience, Inc. (AADI) Q3 2023 Earnings Call Transcript
Unknown11-8
The earnings call highlights several concerns: increasing net loss, high R&D and SG&A expenses, and heavy reliance on a single product (FYARRO). While FYARRO sales grew, they remain modest, and commercialization challenges persist. The PRECISION 1 trial carries significant risks, and management was vague in the Q&A, avoiding specifics on key trial details. Despite having cash reserves, the financial and clinical uncertainties overshadow positive aspects, leading to a negative sentiment.
Aadi Bioscience, Inc. (AADI) Q2 2023 Earnings Call Transcript
Neutral8-9
AADI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
